Literature DB >> 21725854

Intravenous administration of temozolomide as a useful alternative over oral treatment with temozolomide capsules in patients with gliomas.

Kazuya Motomura, Atsushi Natsume, Toshihiko Wakabayashi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21725854     DOI： 10.1007/s11060-011-0651-0

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  3 in total

1.  Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium.

Authors:  Els Everaert; Bart Neyns; Eric Joosens; Theo Strauven; Fabrice Branle; Johan Menten
Journal:  J Neurooncol       Date:  2004-10       Impact factor: 4.130

2.  Temozolomide in the treatment of recurrent malignant glioma.

Authors:  Susan M Chang; Philip Theodosopoulos; Kathleen Lamborn; Mary Malec; Jane Rabbitt; Margaretta Page; Michael D Prados
Journal:  Cancer       Date:  2004-02-01       Impact factor: 6.860

3.  Evaluation of the exposure equivalence of oral versus intravenous temozolomide.

Authors:  Blanca D Diez; Paul Statkevich; Yali Zhu; Malaz A Abutarif; Fengjuan Xuan; Bhavna Kantesaria; David Cutler; Marc Cantillon; Max Schwarz; Maria Guadalupe Pallotta; Fabio H Ottaviano
Journal:  Cancer Chemother Pharmacol       Date:  2009-07-30       Impact factor: 3.333
  3 in total
  2 in total

1.  Aspirin-/TMZ-coloaded microspheres exert synergistic antiglioma efficacy via inhibition of β-catenin transactivation.

Authors:  Zhen-Dong Shi; Xiao-Min Qian; Chao-Yong Liu; Lei Han; Kai-Liang Zhang; Lu-Yue Chen; Jun-Xia Zhang; Pei-Yu Pu; Xu-Bo Yuan; Chun-Sheng Kang
Journal:  CNS Neurosci Ther       Date:  2012-12-11       Impact factor: 5.243

2.  Success at last: a molecular factor that informs treatment.

Authors:  Andrew B Lassman
Journal:  Curr Oncol Rep       Date:  2013-02       Impact factor: 5.075
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.